title: Close correlation between estrogen treatment and renal phosphate reabsorption capacity.
abstract: To determine the influence of estrogen on the activity of renal proximal tubular reabsorption of inorganic phosphate (Pi) in women, we examined the changes of the renal threshold phosphate concentration (also denoted as TmP/GFR), as well as the changes in the concentrations of mineral components in the circulation in two groups of women--one receiving hormone replacement therapy (HRT) and one receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy. We also examined the changes in the concentrations of serum PTH in the GnRH-a group. The patients in the HRT group were continuously treated with 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate per day. The patients in the GnRH-a group were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months. The values of TmP/GFR decreased in all of the patients who received HRT. The mean percentage change in TmP/GFR was -14.5% (range, -24.3% to -9.6%). In contrast, in all of the patients treated with GnRH-a, the values of TmP/GFR increased after 6 months of treatment (the mean percentage change was 28.5%; range, 18.2-78.3%) and returned to the preadministration level at 12 weeks after stopping therapy. In these patients, both the values of TmP/GFR and the concentrations of serum Pi correlated significantly with circulating estradiol levels (r = -0.767, P < 0.01 and r = -0.797, P < 0.01, respectively), but the concentrations of serum corrected calcium did not correlate. Moreover, in the same patients, the levels of serum intact PTH decreased significantly (P < 0.05) after 6 months of treatment, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients. These results suggest that estrogen could act directly to suppress sodium-dependent Pi reabsorption in the renal proximal tubules.
authors.affiliation: Department of Obstetrics and Gynecology, The University of Tokushima, School of Medicine, Japan. uemura@clin.med.tokushima-u.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Uemura
authors.forename: M
authors.initials: M
authors.lastname: Irahara
authors.forename: N
authors.initials: N
authors.lastname: Yoneda
authors.forename: T
authors.initials: T
authors.lastname: Yasui
authors.forename: K
authors.initials: K
authors.lastname: Genjida
authors.forename: K I
authors.initials: KI
authors.lastname: Miyamoto
authors.forename: T
authors.initials: T
authors.lastname: Aono
authors.forename: E
authors.initials: E
authors.lastname: Takeda
mesh_terms: D000328:Adult; D015519:Bone Density; D002979:Climacteric / Q000378:metabolism; D004715:Endometriosis / Q000188:drug therapy / Q000378:metabolism; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy; D005260:Female; D005919:Glomerular Filtration Rate; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D007044:Hysterectomy; D007668:Kidney / Q000378:metabolism*; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000378:metabolism*
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol